SC
NKTR icon

Slow Capital’s Nektar Therapeutics NKTR Stock Holding History

Slow Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-891
Closed -$227K – 176
2020
Q4 		$227K Sell
891
-8
-0.9% -$2.07K 0.05% 169
2020
Q3 		$224K Sell
899
-371
-29% -$117K 0.06% 156
2020
Q2 		$441K Buy
1,270
+28
+2% +$8.74K 0.13% 136
2020
Q1 		$333K Buy
1,242
+143
+13% +$44.2K 0.13% 139
2019
Q4 		$356K Buy
+1,099
New +$319K 0.11% 166
2019
Q3 		– Sell
-738
Closed -$394K – 172
2019
Q2 		$394K Sell
738
-350
-32% -$176K 0.16% 139
2019
Q1 		$548K Sell
1,088
-9
-0.8% -$5.33K 0.22% 120
2018
Q4 		$541K Buy
1,097
+298
+37% +$180K 0.26% 113
2018
Q3 		$730K Buy
799
+32
+4% +$27.3K 0.33% 102
2018
Q2 		$562K Sell
767
-275
-26% -$317K 0.28% 102
2018
Q1 		$1.66M Buy
1,042
+17
+2% +$21.9K 0.75% 56
2017
Q4 		$919K Buy
+1,025
New +$606K 0.48% 77

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Slow Capital's NKTR Position: Q1 2021 in Review

Slow Capital sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 891 shares — an estimated $227K sold.

Slow Capital first reported a position in NKTR in Q4 2017 and held it in 12 quarters. The position peaked at $1.66M in Q1 2018. 236 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

  • Slow Capital reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Slow Capital sold 891 Nektar Therapeutics shares in Q1 2021, an estimated $227K.
  • Slow Capital first reported a position in Nektar Therapeutics in Q4 2017 and held it in 12 quarters.
  • Slow Capital's Nektar Therapeutics position peaked at $1.66M in Q1 2018.
  • 236 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on Slow Capital's 13F filing for Q1 2021, filed 5 May 2021.